drugset
drugset / Trial / NCT01292265

A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

NCT01292265 ↗

Phase 3 Terminated 3 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the changes in joint inflammation produced by Cimzia over 12 week Treatment period measured by Power/Color Doppler and Gray scale Ultrasound.

Timeline

Start
2011-02
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic 200 mg Subcutaneous

Indications

rheumatoid arthritis